ArticleFrontiers in molecular biosciences2025
Progressively exploring and assessing the prognosis of bladder urothelial cancer based on the microenvironment through the integration of multiple databases.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DARS2 serves as an independent prognostic factor and participates in multiple biological processes in bladder urothelial carcinoma.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The heterogeneous prognosis of bladder urothelial carcinoma (BLCA) remains a significant clinical challenge. A multi-factor prognostic model is essential for BLCA, as it not only assesses tumor progression and elucidates underlying molecular mechanisms but also paves the way for timely treatment adjustments and improved clinical decision-making. Methods: Using R software, we performed immunophenotyping on multiple BLCA cohorts from the GEO database to identify shared immune signatures. Simultaneously, we identified BLCA prognosis-associated genes by analyzing TCGA data. Prognostic genes were further refined via LASSO regression, allowing BLCA patients to be stratified into high- and low-risk groups based on their expression patterns. Quantitative PCR (qPCR) was used to validate gene expression in tumor and matched normal tissues. Finally, we integrated clinical data to construct a prognostic model. Results: The GSE31684 and GSE48276 cohorts were divided into high immunity (Immunity_H) and low immunity (Immunity_L) groups, and there were significant microenvironment differences between the Immunity_H and Immunity_L of the two cohorts, and there were many common differentially expressed genes (DEGs) between different immune subtypes of the two cohorts, which were mainly involved in immune-related biological processes. In addition, patients in the high-risk BLCA group exhibited significantly worse prognosis than those in the low-risk group. qPCR analysis confirmed that the expression levels of the risk-stratification genes were significantly different between BLCA tumors and matched adjacent normal tissues. The integrated analysis of tumor mutation burden (TMB) and our risk stratification revealed that patients with low-risk scores and high TMB exhibited the most favorable prognosis. Furthermore, the risk score was validated as an independent prognostic factor through both univariate and multivariate Cox regression analyses. Consequently, we constructed a nomogram that incorporates these findings to assist clinicians in prognostic assessment for BLCA patients. Conclusion: Given that the tumor microenvironment significantly influences BLCA prognosis, our finding that risk stratification serves as an independent prognostic indicator underscores the clinical relevance of our model. This stratification strategy has the potential to improve prognostic assessment and inform personalized treatment planning for BLCA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.